Online inquiry

IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3137MR)

This product GTTS-WQ3137MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets C3&C4 gene. The antibody can be applied in Cardiopulmonary bypass (CPB) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000064.4; NM_001002029.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 718; 721
UniProt ID P01024; P0C0L4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3137MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4271MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ15457MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ5773MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ6316MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ2450MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ6309MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ3011MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ11758MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-1308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW